EUVIMEDObjevte EUVIMED
Beobachtungsstudie

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis

Cindy L Williams, Joanna Billings, Harriet McGowan, Rebecca McDevitt, Charles R Esther, Cameron J McKinzie, William S Wilson, Charissa W Kam

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71038 ↗

At a glance

Beobachtungsstudie in Pediatric Pulmonology, 2025. Written by Cindy L Williams and 7 co-authors. Institution: Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina. Major MEDLINE topics: Cystic Fibrosis, Quinolones, Aminophenols, Anti-Bacterial Agents. Cited 8 times so far (Crossref); 19 references. Funded by: The authors received no specific funding for this work..

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Cystic fibrosis (CF) is a multisystem disease characterized by persistent lung infection. Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) improves respiratory‐related quality of life and reduces rates of infection and antibiotic treatments. Reduced antibiotic use may alter bacterial drug resistance patterns.

Methods

This was a single center, retrospective, observational study analyzing respiratory cultures obtained from people with CF (pwCF) before and after starting ETI therapy. Antibiotic courses and culture data, including susceptibilities, were obtained from the electronic medical record.

Results

There were 312 pwCF on ETI included, with an average age at ETI initiation of 20.9 ± 12.0 years and an average length of time on ETI 2.48 ± 0.69 years. Compared to the pre‐ETI period, pwCF post‐ETI had reductions in the number of antibiotic courses per year (2.5 to 0.7, p < 0.001), antibiotics utilized per course (1.4 to 1.0, p < 0.001), and percentage of courses including intravenous antibiotics (59% to 38%, p < 0.001). The fraction of pwCF with at least one culture positive for Pseudomonas aeruginosa , Burkholderia species, or Stenotrophomonas maltophilia decreased after ETI initiation, though changes were not significant for Staphylococcus aureus . Antibacterial resistance patterns were similar for most antibiotics in pre‐ and post‐ETI periods, with P. aeruginosa exhibiting more resistance to fluoroquinolones post‐ETI. Individuals with resistant organisms pre‐ETI were less likely to clear the pathogen post‐ETI.

Conclusion

Treatment with ETI significantly decreased antibiotic utilization and the prevalence of gram‐negative organisms. Although fewer antibiotics were used, antibiotic resistance remained unchanged or even increased post‐ETI due largely to the greater persistence of resistant organisms.

Subjects

MeSH terms (MEDLINE)

Cystic FibrosisQuinolonesAminophenolsAnti-Bacterial AgentsBenzodioxolesIndolesPyridinesPyrazolesRespiratory Tract InfectionsHumansRetrospective StudiesMaleFemaleDrug CombinationsAdolescentYoung AdultChildAdultChloride Channel AgonistsPyrrolidinesQuinolines

Author keywords

antibiotic resistanceantibiotic susceptibilityantibioticscystic fibrosismicrobiology

Substances

QuinolonesAminophenolsAnti-Bacterial AgentsBenzodioxolesDrug CombinationsIndolesPyridinesPyrazolesivacaftorelexacaftor, ivacaftor, tezacaftor drug combination

Authors and institutions

  • Division of Pediatric Pulmonology, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
  • Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina.

Funding

  • The authors received no specific funding for this work.

Cite

APA

Williams, C. L., Billings, J., McGowan, H., McDevitt, R., Esther, C. R., McKinzie, C. J., Wilson, W. S., & Kam, C. W. (2025). Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71038

Vancouver

Williams CL, Billings J, McGowan H, McDevitt R, Esther CR, McKinzie CJ, et al. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71038

BibTeX
@article{Williams2025,
  author = {Williams, Cindy L and Billings, Joanna and McGowan, Harriet and McDevitt, Rebecca and Esther, Charles R and McKinzie, Cameron J and Wilson, William S and Kam, Charissa W},
  title = {Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71038}
}
Start for free →